Cambridge Catalogue  
  • Help
Home > Catalogue > Antipsychotic Trials in Schizophrenia
Antipsychotic Trials in Schizophrenia

Details

  • 50 b/w illus.
  • Page extent: 330 pages
  • Size: 234 x 156 mm
  • Weight: 0.7 kg

Library of Congress

  • Dewey number: 616.89/8061
  • Dewey version: 22
  • LC Classification: RM333.5 .A58 2010
  • LC Subject headings:
    • CATIE Project
    • Antipsychotic drugs--Testing
    • Schizophrenia--Chemotherapy
    • CATIE Project
    • Schizophrenia--drug therapy

Library of Congress Record

Hardback

 (ISBN-13: 9780521895330)

Antipsychotic medications are a key treatment for schizophrenia and sales of antipsychotic drugs approach $20 billion per year, with fierce marketing between the makers of the drugs. The U.S. National Institute of Mental Health sponsored the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project to provide independent information about the comparative effectiveness of medications. CATIE was the largest, longest and most comprehensive study of schizophrenia to date. Conducted under rigorous double-blind conditions, Antipsychotic Trials in Schizophrenia presents the definitive archival results of this landmark study. The core of the book consists of chapters focused on specific outcomes that set the CATIE findings in a wider context. Also included are chapters on the design, statistical analyses and implications for researchers, clinicians and policy makers. Psychiatrists, psychiatric researchers, mental health policy makers and those working in pharmaceutical companies will all find this to be essential reading.

• Provides an overview of the largest, longest and most comprehensive study of schizophrenia • Includes a chapter on each major outcome area, providing a detailed discussion of CATIE results in the context of other research • Describes the implications for researchers, clinicians and policy makers

Contents

List of contributors; Acknowledgements; Introduction; 1. Study design and protocol development process T. Scott Stroup, Joseph P. McEvoy and Jeffrey A. Lieberman; 2. Statistical considerations Sonia M. Davis, Gary G. Koch, Robert A. Rosenheck and Vicki G. Davis; 3. Effectiveness and efficacy: staying on treatment and symptom reduction Joseph P. McEvoy, T. Scott Stroup and Jeffrey A. Lieberman; 4. Cost-effectiveness and cost-benefit analysis Robert A. Rosenheck and Douglas L. Leslie; 5. Psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study Marvin S. Swartz; 6. Neurocognition Richard S. E. Keefe; 7. Vocational outcomes Sandra G. Resnick and Robert A. Rosenheck; 8. Family outcomes Deborah A. Perlick, Richard Kaczynski and Robert A. Rosenheck; 9. Extrapyramidal side effects Stanley N. Caroff, Del D. Miller and Robert A. Rosenheck; 10. Metabolic side effects and risk of cardiovascular disease Jonathan M. Meyer, Donald C. Goff and Joseph P. McEvoy; 11. Substance use in persons with schizophrenia: incidence, baseline correlates, and effects on outcome Fred Reimherr, Marvin S. Swartz and John L. Olsen; 12. Violence in schizophrenia: prevalence, correlates, and treatment effectiveness Jeffrey Swanson and Richard Van Dorn; 13. Genetic investigations in the CATIE sample James J. Crowley and Patrick F. Sullivan; 14. Human subjects considerations T. Scott Stroup and Paul Appelbaum; 15. Population pharmacokinetics of antipsychotics Kristin L. Bigos, Robert R. Bies, Stephen R. Marder and Bruce G. Pollock; 16. Implications for research design and study implementation T. Scott Stroup and Jeffrey A. Lieberman; 17. Conclusion and implications for practice and policy Robert A. Rosenheck, T. Scott Stroup and Jeffrey A. Lieberman.

Reviews

'… important and timely …' Doody's

'This book is not just a reprint of all published CATIE papers - it takes us beyond the hype of the first publication by reminding us of the breadth and depth of the trial … This book will be of major interest to anyone involved in psychopharmacology. However, the richness of the use of social and cognitive end points means that there is a wealth of information for those who have no interest in antipsychotics but are interested in the lives and outcomes of people with schizophrenia.' The British Journal of Psychiatry

Contributors

Jeffrey Lieberman, Scott Stroup, Joe McEvoy, Sonia Davis, Gary Koch, Bob Rosenheck, Marvin Swartz, Rich Keefe, Sandra Resnick, Deborah Perlick, Stan Caroff, Del Miller, Jonathan Meyer, Don Goff, Fred Reimherr, Jeff Swanson, Richard van Dorn, Patrick Sullivan, Scott Kim, Paul Appelbaum, Bruce Pollock

printer iconPrinter friendly version AddThis